MASSDEVICE ON CALL — California-based lifesciences firm Illumina’s (NSDQ:ILMN) this week unveiled that it had achieved the highly sought $1,000 mark for human DNA sequencing.
Illumina is the 1st group to hit that mark, a highly prized goal of the biotech industry for many years as a signal that full genome sequencing could be truly mainstream.
Illumina’s newly unveiled HiSeq X system can process 20,000 genomes annually for $1,000 apiece, and that the system will be available this quarter, according to Bloomberg.
Insulet readies for black ink in 2014
Insulet (NSDQ:PODD) expects in 2014 to swing to profitability for the 1st time in nearly 14 years, due in large part to the company’s rapidly growing popularity among pediatric diabetics.
Read more
Gore touts another year on FORTUNE’s best companies to work for
W.L. Gore & Associates credited its "non-hierarchical, team-based workplace" with helping land the company again on FORTUNE’s Best 100 Companies to Work For, marking 17 straight years on the list.
Read more
Haemonetics lands tax break for keeping headquarters in Braintree, Mass.
Blood management company Haemonetics (NYSE:HAE) won about $900,000 in tax breaks after convincing a local committee that it needs the assistance to keep its headquarters in Braintree, Mass.
Read more
iPads join the curriculum at George Washington School of Medicine
New medical students entering the George Washington School of Medicine will start school with iPads as part of the standard curriculum.
Read more
